Anticancer Bioscience named a finalist for China Biopharma Leadership Award by Scrip

Anticancer Bioscience named a finalist for China Biopharma Leadership Award by Scrip

Chengdu, China, September 22, 2022 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, is delighted to announce that it has been named as a finalist for the 2022 Scrip Awards in the category of China Biopharma Leadership.

The Scrip Awards, now in its 18th year, is a prestigious annual award that recognizes excellence and achievement in the pharmaceutical and biotech industries. The category of China Biopharma Leadership Award reflects the rapid maturing of China’s biopharma sector and seeks to reward firms that have shown leadership in developing China’s biopharma sector through significant commercial and R&D activity, and by helping patients access new treatments through new launches and successful negotiations with China’s healthcare payers and clinical leaders.

The nomination recognizes ACB’s achievements in producing a promising new drug pipeline. To fuel its pipeline, ACB has constructed proprietary natural product libraries, developed lead-like synthetic compound libraries, and brought machine learning into play to help generate and screen small molecules more efficiently. Since its foundation in 2016, ACB has been focusing on accelerating its five programs toward the clinic. In its most advanced program, a MYC synthetic lethal drug program, ACB has developed inhibitors of a novel target, arising from ACB’s innovative research into MYC synthetic lethality. This MYC-synthetic lethal partner has great potential for the development of first-in-class anticancer therapeutics that attack MYC-expressing cancer.

“Congratulations to all the finalists. We are honored to be recognized with this nomination and are proud to be among a group of esteemed peers in the biopharma sector of China. This recognition reflects the incredible collective efforts of our teams across China, India, Australia, the UK and the US and the progress we have made over the past year. This nomination will motivate all of us toward further success with the development of novel synthetic lethality approaches as the next generation of cancer therapies.” commented the founder and CEO of ACB, Dun Yang, Ph.D..

More about the Scrip Awards 2022

For further information, please contact:

At the company
Anticancer Bioscience:

Media Relations
Scius Communications
Sue Charles
+44 (0) 7968 726585

About Anticancer Bioscience
Anticancer Bioscience (ACB) is an international private company commercializing discoveries emerging from China’s world-leading cancer research at the J. Michael Bishop Institute of Cancer Research. With pioneers in synthetic lethal approaches to precision oncology and experts in MYC biology and cell division, ACB was founded in 2016 in Chengdu, China. ACB is based on over 20 years of collaborative research between the founder Dr. Dun Yang and his Nobel laureate mentor Dr. J. Michael Bishop. It has raised CNY131M (around USD21M) and has around 50 employees in Chengdu, China, Hyderabad, India, Sydney, Australia, St Andrews, UK, and San Francisco, USA.

Follow us on LinkedIn and Twitter.